Your browser doesn't support javascript.
loading
Melphalan flufenamide for relapsed/refractory multiple myeloma.
Nadeem, Omar; Mateos, Maria-Victoria; Efebera, Yvonne A; Paner, Agne; Larocca, Alessandra; Rodríguez-Otero, Paula; Leleu, Xavier; Richardson, Paul G.
Affiliation
  • Nadeem O; Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
  • Mateos MV; Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Centro de Investigación del Cancer (IBMCC-USAL, CSIC), Salamanca, Spain.
  • Efebera YA; Division of Hematology/Blood and Marrow Transplant, OhioHealth, Columbus, Ohio, USA.
  • Paner A; Rush University Medical Center, Chicago, Illinois, USA.
  • Larocca A; Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy.
  • Rodríguez-Otero P; Clínica Universidad de Navarra, Pamplona, Spain.
  • Leleu X; Centre Hospitalier Universitaire de Poitiers, Poitiers, France.
  • Richardson PG; Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA. paul_richardson@dfci.harvard.edu.
Drugs Today (Barc) ; 58(8): 407-423, 2022 Aug.
Article in En | MEDLINE | ID: mdl-35983927
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Multiple Myeloma / Antineoplastic Agents Limits: Humans Language: En Journal: Drugs Today (Barc) Journal subject: MEDICINA OCUPACIONAL / SAUDE AMBIENTAL Year: 2022 Type: Article Affiliation country: United States
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Multiple Myeloma / Antineoplastic Agents Limits: Humans Language: En Journal: Drugs Today (Barc) Journal subject: MEDICINA OCUPACIONAL / SAUDE AMBIENTAL Year: 2022 Type: Article Affiliation country: United States